| P50 | author | Baris Turkbey | Q88769455 |
| | Esther Mena | Q88960898 |
| | Stephanie Harmon | Q90059703 |
| | Peter L Choyke | Q90059714 |
| | Marcin Czarniecki | Q90690731 |
| | Liza Lindenberg | Q97434502 |
| P2093 | author name string | Jan Philipp Radtke | |
| | Marek Cacko | |
| | Frederick Giesel | |
| P2860 | cites work | (68)Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report | Q26747480 |
| | PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges | Q28067404 |
| | Mapping, genomic organization and promoter analysis of the human prostate-specific membrane antigen gene | Q28290465 |
| | Detection rate of PET/CT in patients with biochemical relapse of prostate cancer using [68Ga]PSMA I&T and comparison with published data of [68Ga]PSMA HBED-CC. | Q31145236 |
| | 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy | Q33429398 |
| | German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients | Q33436183 |
| | A Prospective Comparison of 18F-Sodium Fluoride PET/CT and PSMA-targeted 18F-DCFBC PET/CT in Metastatic Prostate Cancer. | Q52618074 |
| | Intraindividual Comparison of 18F-PSMA-1007 PET/CT, Multiparametric MRI, and Radical Prostatectomy Specimens in Patients with Primary Prostate Cancer: A Retrospective, Proof-of-Concept Study. | Q52873027 |
| | Phase 2 Study of 99mTc-Trofolastat SPECT/CT to Identify and Localize Prostate Cancer in Intermediate- and High-Risk Patients Undergoing Radical Prostatectomy and Extended Pelvic LN Dissection. | Q52889779 |
| | 68Ga-PSMA I&T PET/CT for assessment of prostate cancer: evaluation of image quality after forced diuresis and delayed imaging. | Q52984152 |
| | 68Ga-PSMA Positron Emission Tomography/Computed Tomography Provides Accurate Staging of Lymph Node Regions Prior to Lymph Node Dissection in Patients with Prostate Cancer. | Q52985406 |
| | Initial Experience of (68)Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy. | Q53000430 |
| | PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. | Q53131398 |
| | Response and Tolerability of a Single Dose of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Analysis. | Q53790732 |
| | 18F-PSMA-1007 PET/CT Detects Micrometastases in a Patient With Biochemically Recurrent Prostate Cancer. | Q53804455 |
| | Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy | Q60606969 |
| | Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases | Q77378855 |
| | ProstaScint(R) Scan: Contemporary Use in Clinical Practice | Q80297612 |
| | 68Ga-PSMA-617 PET/CT: a promising new technique for predicting risk stratification and metastatic risk of prostate cancer patients | Q88538520 |
| | First Experience With SPECT/CT Using a 99mTc-Labeled Inhibitor for Prostate-Specific Membrane Antigen in Patients With Biochemical Recurrence of Prostate Cancer | Q88616934 |
| | [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study | Q88645082 |
| | NCCN Guidelines Updates: Prostate Cancer and Prostate Cancer Early Detection | Q88763650 |
| | The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer | Q35043569 |
| | Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer. | Q35604902 |
| | Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer | Q35938051 |
| | Sensitivity, Specificity, and Predictors of Positive 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis | Q36065223 |
| | Fluorocholine PET/CT in patients with prostate cancer: initial experience | Q36109495 |
| | Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapy | Q37214430 |
| | Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer | Q37350456 |
| | F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients | Q37662669 |
| | Comparison of hybrid (68)Ga-PSMA-PET/CT and (99m)Tc-DPD-SPECT/CT for the detection of bone metastases in prostate cancer patients: Additional value of morphologic information from low dose CT. | Q38639486 |
| | [(18)F]-DCFPyL Positron Emission Tomography/Magnetic Resonance Imaging for Localization of Dominant Intraprostatic Foci: First Experience. | Q38650299 |
| | Prostate Specific Membrane Antigen Targeted 18F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study | Q38665724 |
| | Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study. | Q38861197 |
| | 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies | Q38862313 |
| | PET Tracers Beyond FDG in Prostate Cancer. | Q39003086 |
| | The Current Status of SPECT or SPECT/CT in South Korea | Q39339421 |
| | 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging | Q39389586 |
| | 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer | Q39449818 |
| | (68)Ga-HBED-CC-PSMA PET/CT Versus Histopathology in Primary Localized Prostate Cancer: A Voxel-Wise Comparison. | Q39572115 |
| | Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer | Q39690658 |
| | Biodistribution of [(68)Ga]PSMA-HBED-CC in Patients with Prostate Cancer: Characterization of Uptake in Normal Organs and Tumour Lesions | Q39869574 |
| | The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions. | Q40621372 |
| | Simultaneous (68)Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer. | Q40959799 |
| | Detection and characterization of the prostate‐specific membrane antigen (PSMA) in tissue extracts and body fluids | Q41297571 |
| | Comparison of [(18)F]DCFPyL and [ (68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer | Q41319390 |
| | (18)F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617. | Q41774400 |
| | Novel Preclinical and Radiopharmaceutical Aspects of [68Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer | Q41905456 |
| | Comparison of Prostate-Specific Membrane Antigen-Based 18F-DCFBC PET/CT to Conventional Imaging Modalities for Detection of Hormone-Naïve and Castration-Resistant Metastatic Prostate Cancer | Q42060482 |
| | PSMA-Based [(18)F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer | Q42328242 |
| | Time trends in biochemical recurrence after radical prostatectomy: results of the SEARCH database | Q42596143 |
| | ¹⁸F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer | Q43156292 |
| | 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen: pharmacokinetics and biodistribution studies in healthy subjects and patients with metastatic prostate cancer | Q44247995 |
| | 68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. | Q46225464 |
| | 99m Tc-MIP-1404-SPECT/CT for the detection of PSMA-positive lesions in 225 patients with biochemical recurrence of prostate cancer | Q47438555 |
| | Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score | Q47965751 |
| | Comparison of standard and delayed imaging to improve the detection rate of [68Ga]PSMA I&T PET/CT in patients with biochemical recurrence or prostate-specific antigen persistence after primary therapy for prostate cancer | Q48141689 |
| | Comparison of PSMA-HBED and PSMA-I&T as diagnostic agents in prostate carcinoma. | Q48188322 |
| | Intra-individual comparison of Tc-99m-MDP bone scan and the PSMA-ligand Tc-99m-MIP-1427 in patients with osseous metastasized prostate cancer | Q49680783 |
| | Combined model-based and patient-specific dosimetry for 18F-DCFPyL, a PSMA-targeted PET agent | Q49827187 |
| | Assessment of PSMA targeting ligands bearing novel chelates with application to theranostics: Stability and complexation kinetics of 68Ga3+, 111In3+, 177Lu3+ and 225Ac3. | Q50064317 |
| | Biochemical recurrence of prostate cancer: initial results with 18F-PSMA-1007 PET/CT. | Q50118705 |
| | Fluorine-18 Prostate-specific Membrane Antigen-1007 Positron Emission Tomography/Computed Tomography and Multiparametric Magnetic Resonance Imaging in Diagnostics of Local Recurrence in a Prostate Cancer Patient After Recent Radical Prostatectomy | Q50126603 |
| | 18F-DCFBC Prostate-Specific Membrane Antigen-Targeted PET/CT Imaging in Localized Prostate Cancer: Correlation With Multiparametric MRI and Histopathology | Q50430295 |
| | Multiple Time-Point 68Ga-PSMA I&T PET/CT for Characterization of Primary Prostate Cancer: Value of Early Dynamic and Delayed Imaging. | Q50881222 |
| | Convenient Preparation of [(68)Ga]DKFZ-PSMA-11 Using a Robust Single-Vial Kit and Demonstration of Its Clinical Efficacy. | Q51440427 |
| | A Magnetic Resonance Imaging-Based Prediction Model for Prostate Biopsy Risk Stratification. | Q51748930 |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | reproductive medicine | Q351870 |
| | urology | Q105650 |
| P304 | page(s) | 831-843 | |
| P577 | publication date | 2018-10-01 | |
| P1433 | published in | Translational andrology and urology | Q27724139 |
| P1476 | title | Keeping up with the prostate-specific membrane antigens (PSMAs): an introduction to a new class of positron emission tomography (PET) imaging agents | |
| P478 | volume | 7 | |